Seagen and Nurix Forge a Cutting-Edge Alliance to Unleash Revolutionary Cancer-Killing Antibody Conjugates

Seagen and Nurix Unite Forces in $3.4 Billion Quest to Revolutionize Cancer Treatment

In a groundbreaking collaboration, Seagen and Nurix Therapeutics are set to rewrite the playbook on cancer therapies with their pioneering approach—degrader-antibody conjugates (DACs)—crafted to selectively exterminate cancer cells.

Under the terms of this strategic alliance, Seagen is making an initial payment of $60 million, committing to a staggering $3.4 billion for research, development, regulatory, and commercial milestones. Nurix will also bask in mid-single to low-double digit tiered royalties on future sales, reaping the rewards of their innovative partnership.

But the excitement doesn’t stop there. California-based Nurix will have the option for profit-sharing and co-promotion in the U.S. for two products stemming from this partnership.

Together, Seagen and Nurix will weave their collective expertise to conjure DACs—a fusion of antibodies’ precision and the potent, catalytic degradation of cancer driver proteins, as eloquently described by Nurix CEO Arthur Sands.

Their secret weapon? Nurix’s proprietary DELigase platform, a treasure trove of E3 ligases and DNA-encoded libraries of small molecules, is harnessed to identify candidates that can manipulate target protein levels. Seagen will handpick multiple targets for this groundbreaking approach, spearheading the task of coupling Nurix’s degraders with antibodies, shepherding DAC candidates through preclinical and clinical development, and ultimately spearheading commercialization.

The possibilities are vast, as this collaboration opens the door to multiple DAC drug products, each with its unique protein degraders.

While antibody-drug conjugates (ADCs) have already carved their niche by combining monoclonal antibodies with chemotherapy drugs, DACs are taking the concept to a whole new level. Instead of toxic chemotherapeutic agents, DACs wield protein degraders powered by E3 ligase enzymes, surgically dismantling specific problematic proteins.

As William Figg, an oncologist at the National Institutes of Health, aptly puts it, DACs combine “the benefits of targeted therapy with the cytotoxicity of chemotherapy.”

In essence, DACs represent the dawn of a new era in cancer treatment, holding the promise to transform the landscape for a wide spectrum of solid tumors and hematologic malignancies, as underscored by Nurix CEO Arthur Sands.

Leave a Comment